Third Rock Ventures IV, L.P.
SEC CIK 1688327 · EDGAR
BoughtSold
Most active insiders at MAZE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bernstein Harold | Pres, CMO, R, D | — | $9.02M |
| 2 | Coloma Jason V | CEO, Dir | — | $5.25M |
| 3 | Dandekar Atul | CSBO | — | $5.01M |
| 4 | Bachrodt Amy | SVP, Fin | — | $1.56M |
| 5 | Sohn Catherine A. | Dir | — | $1.15M |
| 6 | Courtney Phillips | GC, Corp. Sec | — | $104.8K |
| 7 | Third Rock Ventures GP V, LP | 10% | — | — |
| 8 | HOMCY CHARLES J | Dir | — | — |
Third Rock Ventures IV, L.P. made no open-market trades at MAZE in the last 12 months.
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-02-04 | 2025-02-03 | MAZE | Maze Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% | C - Cnv Deriv | $0.00 | +950.8K | 950.8K | New | $0 |
| D | 2025-02-04 | 2025-02-03 | MAZE | Maze Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% | C - Cnv Deriv | $0.00 | +5.76M | 6.07M | +1,852% | $0 |
| 2024-09-04 | 2024-08-30 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% | S - Sale | $11.60 | -175.0K | 17.00M | -1% | -$2.03M | |
| 2024-08-29 | 2024-08-27 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% | S - Sale | $11.55 | -25.0K | 17.18M | -0.1% | -$288.8K | |
| M | 2024-07-26 | 2024-07-24+ | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% | S - Sale | $9.84 | -300.6K | 17.87M | -2% | -$2.96M |
| 2024-07-22 | 2024-07-18 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% | S - Sale | $9.81 | -191.5K | 18.46M | -1% | -$1.88M | |
| 2024-02-21 | 2024-02-20 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% | S - Sale | $12.00 | -162.5K | 19.20M | -0.8% | -$1.95M |
Purchase Sale Sale after option exercise All abbreviations